Want to see ASND full AI Analyst Report?
ASND Stock Chart & Stats
$244.48
-$0.55(-0.40%)
At close: 4:00 PM EST
$244.48
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$160.86 - $282.15
Previous CloseN/A
Volume129.18K
Average Volume (3M)808.41K
Market Cap
$17.29B
Enterprise Value$12.79B
Total Cash (Recent Filing)$573.42M
Total Debt (Recent Filing)$897.60M
Price to Earnings (P/E)29.4
Beta0.69
Next Earnings
Aug 06, 2026EPS Estimate
1.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.19
Shares Outstanding62,376,846
10 Day Avg. Volume1,164,549
30 Day Avg. Volume808,407
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue14.75
Enterprise Value/Gross Profit16.73
Enterprise Value/Ebitda1.03K
Forecast
1Y Price Target
$308.92Price Target Upside26.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)13.37
Revenue Forecast (FY)$1.33B
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Revenue GrowthVery high gross margins (~88% TTM) combined with multi-year revenue step-up and Q1 €247M sales indicate attractive unit economics and scalable product pricing. Durable margins provide structural room to absorb SG&A/R&D as commercialization scales and support long-term operating‑margin improvement if volume growth persists.
Improving Cash Generation And LiquidityOperating and free cash flow have turned positive (TTM), and Q1 cash of €573M plus monetization of a PRV ($187.5M) and redemption of convertible notes materially boost near‑term liquidity. This strengthens funding flexibility for commercialization and trials and reduces reliance on dilutive financings over the medium term.
Strong Commercial Momentum & ApprovalsRapid uptake of YORVIPATH (€197M Q1; >1,000 new U.S. patients) and FDA approval plus immediate prescriptions for YUVIWEL demonstrate durable commercial execution, expanding prescriber base and payer access. These product-level traction points underpin predictable recurring revenue streams and support economies of scale in global commercialization.
Bears Say
Meaningful Leverage And Past Negative EquityA sizeable debt load (~$0.9B) and history of negative equity constrain financial flexibility. If operating margins fail to sustainably improve, debt servicing and covenant pressures could force dilutive financings or cutbacks in R&D/commercial investment, impeding long‑term growth prospects despite recent cash inflows.
Earnings Quality Reliant On One-offsThe large GAAP profit is materially explained by a one‑time deferred tax asset; underlying operations still show operating losses historically and modest operating cash conversion. Reliance on accounting one‑offs and non‑recurring items raises sustainability questions about reported profitability and cash‑backed earnings.
Regulatory, Legal And Supply UncertaintiesOngoing ITC/legal matters and supply/capacity timing for YUVIWEL create persistent execution risk that could delay shipments, constrain uptake, or increase costs. Such structural regulatory and manufacturing uncertainties can slow revenue ramp and erode payer/provider confidence over multiple quarters.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $160.86 and its highest was $282.15 in the past 12 months.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market cap is $17.29B.
When is Ascendis Pharma A/S’s upcoming earnings report date?
Ascendis Pharma A/S’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Ascendis Pharma A/S’s earnings last quarter?
Ascendis Pharma A/S released its earnings results on May 07, 2026. The company reported $11.133 earnings per share for the quarter, beating the consensus estimate of $0.185 by $10.948.
Is Ascendis Pharma A/S overvalued?
According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued.
Does Ascendis Pharma A/S pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
What is Ascendis Pharma A/S’s EPS estimate?
Ascendis Pharma A/S’s EPS estimate is 1.74.
How many shares outstanding does Ascendis Pharma A/S have?
Ascendis Pharma A/S has 62,376,846 shares outstanding.
What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
Ascendis Pharma A/S reported an EPS of $11.133 in its last earnings report, beating expectations of $0.185. Following the earnings report the stock price went up 4.341%.
Which hedge fund is a major shareholder of Ascendis Pharma A/S?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$308.92 (26.36% Upside)
$308.92 (26.36% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 302.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.75%
12-Months-Change
Fundamentals
Return on Equity
-5641.90%
Trailing 12-Months
Asset Growth
101.31%
Trailing 12-Months
Company Description
Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
ASND Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial achievements—rapid revenue generation (EUR 247M Q1), robust YORVIPATH adoption (>1,000 new U.S. patients in the quarter; >6,300 cumulative), YUVIWEL FDA approval with early prescriptions, solid non-IFRS profitability and a healthy cash position augmented by a USD 187.5M PRV sale—supporting a growth and commercialization narrative. Offsetting items include one-time EUR 15M Q1 headwinds, elevated noncash finance expense (EUR 63M), GAAP net profit driven by a large deferred tax asset, rising SG&A, an R&D decline influenced by an inventory write-up, and the discontinuation of an internal oncology program. Overall, positives around product approvals, commercial traction, pipeline data (notably the COACH combo), and balance sheet actions outweigh the listed lowlights, though some one-time accounting and legal/operational uncertainties temper near-term clarity.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$308.92
▲(26.36% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
<0.01% Insiders
11.85% Mutual Funds
0.52% Other Institutional Investors
83.86% Public Companies and
Individual Investors